ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,28
-0,20%
Bitcoin
70 179,36
0,07%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. InVivo Therapeutics Holdings Corporation (NVIV)

  7. InVivo Therapeutics Holdings Corporation (NVIV) Actualités

NVIV

InVivo Therapeutics (NVIV)

InVivo Therapeutics Holdings Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NVIV
DateHeureSourceTitreSymboleSociété
21/03/202419h23Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
14/02/202420h53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
07/02/202420h12Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
07/02/202419h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
06/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
05/12/202314h35Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
05/12/202314h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
08/11/202322h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
12/05/202322h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
25/04/202323h38Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
09/03/202315h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
09/03/202314h55Business WireInVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord InjuryNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
01/03/202322h35Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
22/11/202212h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
21/11/202223h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
09/11/202212h02Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
07/11/202223h26Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
11/10/202222h28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
11/10/202222h01Business WireInVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
11/10/202217h08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
07/10/202214h00Business WireInVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
09/09/202214h00Business WireInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
06/09/202212h02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
18/08/202215h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
11/08/202222h03Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
13/07/202214h30Business WireInVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General CounselNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
08/07/202222h32Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NVIVInVivo Therapeutics Holdings Corporation
08/06/202214h30Business WireInVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed NeurosurgeryNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
02/06/202214h30Business WireInVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury StudyNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
14/04/202222h30Business WireInVivo Therapeutics Announces Reverse Stock SplitNASDAQ:NVIVInVivo Therapeutics Holdings Corporation
 Showing the most relevant articles for your search:NASDAQ:NVIV

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
DG
Vinci
SPI
SP500
S&P 500
EU
CS
Axa
EU
BNP
BNP Paribas
EU
RNO
Renault
EU
EN
Bouygues
EU
ML
Michelin
EU
CAP
Capgemini
NYSE
JPM
JP Morgan Chase
EU
SGO
Cie de SaintGobain
EU
HO
Thales
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
EU
LR
Legrand
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés